Automated classification of tertiary lymphoid structures in colorectal cancer using TLS-PAT artificial intelligence tool
- PMID: 40119179
- PMCID: PMC11928541
- DOI: 10.1038/s41598-025-94664-0
Automated classification of tertiary lymphoid structures in colorectal cancer using TLS-PAT artificial intelligence tool
Abstract
Colorectal cancer (CRC) ranks as the third most common and second deadliest cancer worldwide. The immune system, particularly tertiary lymphoid structures (TLS), significantly influences CRC progression and prognosis. TLS maturation, especially in the presence of germinal centers, correlates with improved patient outcomes; however, consistent and objective TLS assessment is hindered by varying histological definitions and limitations of traditional staining methods. This study involved 656 patients with colorectal adenocarcinoma from CHU Brest, France. We employed dual immunohistochemistry staining for CD21 and CD23 to classify TLS maturation stages in whole-slide images and implemented a fivefold cross-validation. Using ResNet50 and Vision Transformer models, we compared various aggregation methods, architectures, and pretraining techniques. Our automated system, TLS-PAT, achieved high accuracy (0.845) and robustness (kappa = 0.761) in classifying TLS maturation, particularly with the Vision Transformer pretrained on ImageNet using Max Confidence aggregation. This AI-driven approach offers a standardized method for automated TLS classification, complementing existing detection techniques. Our open-source tools are designed for easy integration with current methods, paving the way for further research in external datasets and other cancer types.
Keywords: Artificial intelligence; Colorectal cancer; Deep learning; Immunohistochemistry; QuPath; Tertiary lymphoid structures.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethical approval: The present observational, non-interventional study was conducted in compliance with the Declaration of Helsinki, following approval by our institutional review board, which waived the requirement for patients’ consent for the analyses (Ethic Committee of CHU Brest, B2024CE.42–29BRC24.0204). All patient data were anonymized to protect privacy and confidentiality. All samples were issued for the sample collection of CHU Brest Pathology Department (CPP n° AC-2019-3642) and the data of Finistère Registry of Digestive Tumors were registered by the French Data Protection Authority (CNIL, authorization n° 998024). The quality and completeness of the Finistere Digestive cancer registry are certified every four years by an audit conducted by the National Cancer Institute (INCa), the National Institute of Health and Medical Research (INSERM), and the National Public Health Institute.
Figures





References
-
- Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021). - PubMed
-
- Hayase, S. et al. Fibroblast activation protein and tertiary lymphoid structure in colorectal cancer recurrence. Anticancer Res.42(12), 5897–5907 (2022). - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical